Low-dose ranitidine for the relief of heartburn

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 4, 1999, Pages 459-465

  Pappa, K A ^a,b   Gooch, W M ^a   Buaron, K ^a   Payne, J E ^a   Giefer, E E ^a   Sirgo, M A ^a   Ciociola, A A ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEARTBURN; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); RANITIDINE; TREATMENT OUTCOME;

EID: 0032891744     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00507.x     Document Type: Article

References (12)

1. Richter JE. Heartburn, dysphagia, odynophagia, and other esophageal symptoms. In: Sleisenger MH, Fortran JS, eds. Gastrointestinal Disease. 5th Edn. Philadelphia: WB Saunders Co, 1993: 331-40.
2. Heartburn Incidence, Awareness, and Usage Study. Briskin Research, Wave I; March 1994; Wave II: August 1994.
3. Castell DO. Introduction to pathophysiology of gastroesophageal reflux: In: Castell DO, Wu WC, Ott DJ, eds. Gastroesophageal Reflux Disease: Pathogenesis, Diagnosis, Therapy. New York: Futura Publishing. 1985: 3-9.
4. Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990; 19(3): 683-712.
5. Brunton LL. Agents for control of gastric acidity and treatment of peptic ulcers. In: Gilman AG, ed. The Pharmacological Basis of Therapeutics, 4th Edn. New York: Pergamon Press, 1990: 897-923.
6. Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R. Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial. Arch Intern Med 1987; 147: 1485-91.
7. Hamilton MR, Sercombe JC, Pounder RE, Snell CC. Intragastric acidity following low doses of ranitidine and famotidine. Pharmacology 1996; 16: 511-12.
8. Grimley C, Constantinides S, Snell CC, Mills JG, Nwokolo CM. Prolonged inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75mg: A comparative study with cimetidine and placebo. Aliment Pharmacol Ther 1997; 11: 875-9.
9. Wyeth JW, Pounder RE, Sercombe JC, Snell CC. The effect of low-doses of ranitidine on intragastric acidity in healthy men. Aliment Pharmacol Ther 1998; 12: 255-61.
10. Merck and Co. Public Presentation of Pepcid OTC to Joint GI and Non-Prescription Advisory Committee; July 27-29 1994, Washington, DC.
11. Sirgo MA, Schachtel BP. Development of gastrointestinal drugs for over-the counter indications. In: Friedman G, Jacobson ED, McCallum RW, eds. Gastrointestinal Pharmacology & Therapeutics, 1st Edn. Philadelphia: Lippincott-Raven, 1977: 728.
12. Mills JG, Koch KM, Webster C, Sirgo MA, Fitzgerald K, Wood JR. The safety of ranitidine in over a decade of use. Aliment Pharmacol Ther 1997; 11: 129-137.